Announcement • Apr 29
Syschem (India) Limited to Report Q4, 2026 Results on May 25, 2026 Syschem (India) Limited announced that they will report Q4, 2026 results on May 25, 2026 Recent Insider Transactions • Feb 16
MD & Director recently sold ₹8.5m worth of stock On the 13th of February, Ranjan Jain sold around 160k shares on-market at roughly ₹52.87 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ranjan has been a net seller over the last 12 months, reducing personal holdings by ₹12m. Reported Earnings • Feb 04
Third quarter 2026 earnings released: EPS: ₹0.96 (vs ₹0.13 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.96 (up from ₹0.13 in 3Q 2025). Revenue: ₹1.62b (up 77% from 3Q 2025). Net income: ₹41.7m (up ₹36.7m from 3Q 2025). Profit margin: 2.6% (up from 0.6% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹54.41, the stock trades at a trailing P/E ratio of 52.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years. Announcement • Jan 19
Syschem (India) Limited to Report Q3, 2026 Results on Feb 02, 2026 Syschem (India) Limited announced that they will report Q3, 2026 results on Feb 02, 2026 Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹54.93, the stock trades at a trailing P/E ratio of 52.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 10% over the past three years. Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹0.44 (vs ₹0.16 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹0.44 (up from ₹0.16 loss in 2Q 2025). Revenue: ₹1.18b (up 118% from 2Q 2025). Net income: ₹19.0m (up ₹25.4m from 2Q 2025). Profit margin: 1.6% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Announcement • Oct 24
Syschem (India) Limited to Report Q2, 2026 Results on Nov 10, 2025 Syschem (India) Limited announced that they will report Q2, 2026 results on Nov 10, 2025 Reported Earnings • Aug 05
First quarter 2026 earnings released: EPS: ₹0.38 (vs ₹0.03 in 1Q 2025) First quarter 2026 results: EPS: ₹0.38 (up from ₹0.03 in 1Q 2025). Revenue: ₹1.27b (up 24% from 1Q 2025). Net income: ₹16.7m (up ₹15.4m from 1Q 2025). Profit margin: 1.3% (up from 0.1% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Announcement • Aug 04
Syschem (India) Limited, Annual General Meeting, Sep 04, 2025 Syschem (India) Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time. Announcement • Jul 07
Syschem (India) Limited to Report Q1, 2026 Results on Aug 04, 2025 Syschem (India) Limited announced that they will report Q1, 2026 results on Aug 04, 2025 Recent Insider Transactions • May 26
MD & Director recently sold ₹3.2m worth of stock On the 23rd of May, Ranjan Jain sold around 75k shares on-market at roughly ₹42.06 per share. This transaction amounted to 2.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ranjan's only on-market trade for the last 12 months. Reported Earnings • May 11
Full year 2025 earnings released Full year 2025 results: Revenue: ₹3.86b (up 65% from FY 2024). Net income: ₹4.60m (down 83% from FY 2024). Profit margin: 0.1% (down from 1.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings. Announcement • May 03
Syschem (India) Limited to Report Q4, 2025 Results on May 08, 2025 Syschem (India) Limited announced that they will report Q4, 2025 results on May 08, 2025 Announcement • Jan 24
Syschem (India) Limited to Report Q3, 2025 Results on Feb 04, 2025 Syschem (India) Limited announced that they will report Q3, 2025 results on Feb 04, 2025 New Risk • Dec 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹2.09b market cap, or US$24.6m). Reported Earnings • Nov 09
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: ₹542.1m (up 24% from 2Q 2024). Net loss: ₹6.40m (down 157% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth. Announcement • Oct 28
Syschem (India) Limited to Report Q3, 2025 Results on Nov 08, 2024 Syschem (India) Limited announced that they will report Q3, 2025 results on Nov 08, 2024 Board Change • Sep 25
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman Arshdeep Kaur was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹0.03 (vs ₹0.44 in 1Q 2024) First quarter 2025 results: EPS: ₹0.03 (down from ₹0.44 in 1Q 2024). Revenue: ₹1.02b (up 117% from 1Q 2024). Net income: ₹1.37m (down 90% from 1Q 2024). Profit margin: 0.1% (down from 3.0% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 71% per year, which means it is significantly lagging earnings growth. Announcement • Aug 09
Syschem (India) Limited Approves Appointment of Vivek Trehan as (Non-Executive) Director Syschem (India) Limited at the Annual General Meeting held on August 07, 2024 approved appointment of Mr. Vivek Trehan, as (Non-Executive) Director of the Company. Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹46.24, the stock trades at a trailing P/E ratio of 66.8x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 507% over the past three years. Announcement • Jul 25
Syschem (India) Limited to Report Q1, 2025 Results on Aug 12, 2024 Syschem (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Reported Earnings • Jul 08
Full year 2024 earnings released: EPS: ₹0.78 (vs ₹1.53 in FY 2023) Full year 2024 results: EPS: ₹0.78 (down from ₹1.53 in FY 2023). Revenue: ₹2.34b (up 79% from FY 2023). Net income: ₹27.6m (down 39% from FY 2023). Profit margin: 1.2% (down from 3.5% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth. Announcement • Jul 04
Syschem (India) Limited, Annual General Meeting, Aug 07, 2024 Syschem (India) Limited, Annual General Meeting, Aug 07, 2024, at 15:30 Indian Standard Time. Announcement • Jun 27
Syschem (India) Limited Announces Resignation of Neena Batra as Non Executive, Director Syschem (India) Limited announced that Mrs. Neena Batra vide her letter dated 27th June, 2024 has submitted her resignation as Non Executive, Director of the Company with Immediate effect due to her preoccupation and other professional Commitments. Announcement • Apr 29
Syschem (India) Limited to Report Q4, 2024 Results on May 06, 2024 Syschem (India) Limited announced that they will report Q4, 2024 results on May 06, 2024 Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹66.49, the stock trades at a trailing P/E ratio of 77.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 940% over the past three years. Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: ₹0.06 (vs ₹0.67 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.06 (down from ₹0.67 in 3Q 2023). Revenue: ₹515.2m (up 49% from 3Q 2023). Net income: ₹2.32m (down 89% from 3Q 2023). Profit margin: 0.4% (down from 6.0% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 98% per year and the company’s share price has also increased by 98% per year. Announcement • Jan 29
Syschem (India) Limited to Report Q3, 2024 Results on Feb 09, 2024 Syschem (India) Limited announced that they will report Q3, 2024 results on Feb 09, 2024 Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹60.30, the stock trades at a trailing P/E ratio of 45.7x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 904% over the past three years. New Risk • Nov 13
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.8% Last year net profit margin: 4.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (2.8% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₹2.05b market cap, or US$24.6m). Reported Earnings • Nov 13
Second quarter 2024 earnings released: EPS: ₹0.35 (vs ₹0.48 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.35 (down from ₹0.48 in 2Q 2023). Revenue: ₹436.8m (up 93% from 2Q 2023). Net income: ₹11.2m (down 17% from 2Q 2023). Profit margin: 2.6% (down from 5.9% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹53.20, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 978% over the past three years. Announcement • Nov 01
Syschem (India) Limited to Report Q2, 2024 Results on Nov 06, 2023 Syschem (India) Limited announced that they will report Q2, 2024 results on Nov 06, 2023 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹67.57, the stock trades at a trailing P/E ratio of 47.7x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 846% over the past three years. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹56.77, the stock trades at a trailing P/E ratio of 40.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 846% over the past three years. Announcement • Aug 05
Syschem (India) Limited, Annual General Meeting, Sep 23, 2023 Syschem (India) Limited, Annual General Meeting, Sep 23, 2023, at 15:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹45.48, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 640% over the past three years. New Risk • Aug 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₹1.32b market cap, or US$16.0m). Announcement • Jul 29
Syschem (India) Limited to Report Q1, 2024 Results on Aug 04, 2023 Syschem (India) Limited announced that they will report Q1, 2024 results on Aug 04, 2023 New Risk • Jun 08
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (₹1.28b market cap, or US$15.5m). Reported Earnings • Jun 08
Full year 2023 earnings released: EPS: ₹0.14 (vs ₹0.76 loss in FY 2022) Full year 2023 results: EPS: ₹0.14 (up from ₹0.76 loss in FY 2022). Revenue: ₹1.31b (up 99% from FY 2022). Net income: ₹45.1m (up ₹62.2m from FY 2022). Profit margin: 3.5% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹49.55, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 720% over the past three years. Announcement • May 07
Syschem (India) Limited to Report Q4, 2023 Results on May 15, 2023 Syschem (India) Limited announced that they will report Q4, 2023 results on May 15, 2023 Reported Earnings • Jan 23
Third quarter 2023 earnings released: EPS: ₹0.67 (vs ₹0.43 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹0.67 (up from ₹0.43 loss in 3Q 2022). Revenue: ₹346.2m (up 217% from 3Q 2022). Net income: ₹20.7m (up ₹30.7m from 3Q 2022). Profit margin: 6.0% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 21
Syschem (India) Limited Announces Board Resignations Syschem (India) Limited at its board of directors meeting held on January 21, 2023 accepted resignation of Mrs. Jasvir kaur Daljeetsingh Sidhu as independent director and Mr. Rahul Goyat as Independent Director board accepted the same with immediate effect. Announcement • Jan 12
Syschem (India) Limited to Report Q3, 2023 Results on Jan 20, 2023 Syschem (India) Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Jan 20, 2023 Recent Insider Transactions • Dec 20
Insider recently sold ₹193k worth of stock On the 14th of December, Naresh Batra sold around 5k shares on-market at roughly ₹42.92 per share. This transaction amounted to 6.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹4.5m. Insiders have been net sellers, collectively disposing of ₹7.7m more than they bought in the last 12 months. Announcement • Dec 14
Syschem (India) Limited announced a financing transaction Syschem (India) Limited announced a private placemat of 1,350,000 convertible warrants on December 12, 2022. 25% of the allotment price will be paid by the allottees in to the Bank Account at the time of subscription. Further the holder of 13,50,000 convertible warrants have paid the balance 75% of the consideration and exercised their right of conversion. The transaction will include participation from Ranjan Jain. The transaction has been approved by the board of directors of the company. Board Change • Dec 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Chairman Rahul Goyat was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Nov 29
Whole-Time Director recently sold ₹4.5m worth of stock On the 28th of November, Suninder Singh sold around 100k shares on-market at roughly ₹44.90 per share. This transaction amounted to 9.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹7.4m more than they bought in the last 12 months. Announcement • Oct 28
Syschem (India) Limited to Report Q2, 2023 Results on Nov 02, 2022 Syschem (India) Limited announced that they will report Q2, 2023 results at 11:00 AM, Indian Standard Time on Nov 02, 2022 Recent Insider Transactions • Sep 01
Non-Executive Non-Independent Director recently sold ₹282k worth of stock On the 29th of August, Neena Batra sold around 7k shares on-market at roughly ₹43.33 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹364k more than they bought in the last 12 months. Announcement • Aug 20
Syschem (India) Limited, Annual General Meeting, Sep 16, 2022 Syschem (India) Limited, Annual General Meeting, Sep 16, 2022, at 16:00 Indian Standard Time. Reported Earnings • Jul 28
First quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.69 loss in 1Q 2022) First quarter 2023 results: EPS: ₹0.56 (up from ₹0.69 loss in 1Q 2022). Revenue: ₹164.1m (down 16% from 1Q 2022). Net income: ₹7.10m (up ₹22.0m from 1Q 2022). Profit margin: 4.3% (up from net loss in 1Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 63% per year, which means it is well ahead of earnings. Announcement • Jul 19
Syschem (India) Limited to Report Q1, 2023 Results on Jul 27, 2022 Syschem (India) Limited announced that they will report Q1, 2023 results at 12:15 PM, Indian Standard Time on Jul 27, 2022 Announcement • Jun 28
Syschem (India) Limited announced that it has received INR 85.25 million in funding On June 27, 2022, Syschem (India) Limited closed the transaction. The transaction will included participation from Virendra Popatlal Shah for 12,50,000 shares, Bhavesh Virendra Shah for 7,50,000 shares, Bimal Virendra Shah for 7,50,000 shares, Dinesh Jagdishchandra Khokhani for 7,50,000 shares, Mahesh Jagdishchandra Khokhani for 12,50,000 shares, and Mehul Jagdishchandra Kokhani for 7,50,000 shares. Recent Insider Transactions • Jun 13
Chief Financial Officer recently sold ₹112k worth of stock On the 10th of June, Sanjeev Agrawal sold around 6k shares on-market at roughly ₹19.98 per share. This was the largest sale by an insider in the last 3 months. This was Sanjeev's only on-market trade for the last 12 months. Reported Earnings • Jun 03
Full year 2022 earnings released: ₹0.76 loss per share (vs ₹2.70 loss in FY 2021) Full year 2022 results: ₹0.76 loss per share (up from ₹2.70 loss in FY 2021). Revenue: ₹657.6m (down 12% from FY 2021). Net loss: ₹17.1m (loss narrowed 69% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Announcement • May 21
Syschem (India) Limited announced that it expects to receive INR 85.25 million in funding Syschem (India) Limited announced that it will issue up to maximum of 5,500,000 common shares at a price of INR 15.5 per share for gross proceeds of INR 85,250,000 on May 19, 2022. The transaction will include participation from VirendraPopatlal Shah, BhaveshVirendra Shah, BimalVirendra Shah, Dinesh JagdishchandraK okhani, Mahesh JagdishchandraK okhani, and MehulJagdishchandraKokhani. The company has entered into share subscription agreement with investors. The company will receive funding through preferential allotment. The transaction has been approved by board of directors of the company and is subject to approval from shareholders and applicable regulatory authorities. Announcement • May 20
Syschem (India) Limited to Report Q4, 2022 Results on May 27, 2022 Syschem (India) Limited announced that they will report Q4, 2022 results on May 27, 2022 Reported Earnings • Feb 11
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹0.43 loss per share (up from ₹0.72 loss in 3Q 2021). Revenue: ₹109.4m (down 46% from 3Q 2021). Net loss: ₹9.94m (loss narrowed 36% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 12
Second quarter 2022 earnings released: ₹0.74 loss per share (vs ₹0.47 loss in 2Q 2021) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2022 results: Revenue: ₹126.9m (down 34% from 2Q 2021). Net loss: ₹17.1m (loss widened 70% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 04
Full year 2021 earnings released: ₹2.58 loss per share (vs ₹0.99 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: ₹746.7m (down 15% from FY 2020). Net loss: ₹55.7m (loss widened 200% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 10
Third quarter 2021 earnings released: ₹0.72 loss per share (vs ₹0.84 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹200.6m (up 14% from 3Q 2020). Net loss: ₹15.4m (loss narrowed 2.0% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 06
New 90-day high: ₹8.33 The company is up 40% from its price of ₹5.95 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Announcement • Jan 27
Syschem (India) Limited to Report Q3, 2021 Results on Feb 08, 2021 Syschem (India) Limited announced that they will report Q3, 2021 results on Feb 08, 2021 Is New 90 Day High Low • Jan 08
New 90-day high: ₹7.78 The company is up 23% from its price of ₹6.32 on 09 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Dec 14
New 90-day high: ₹7.27 The company is up 26% from its price of ₹5.76 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Announcement • Nov 18
Syschem (India) Limited Appoints Shikha Kataria as Company Secretary and Compliance Officer Syschem (India) Limited announced that Ms. Shikha Kataria has been appointed as Company Secretary and Compliance Officer of the company with effect from November 17, 2020. Announcement • Nov 12
Syschem (India) Limited Announces Resignation of Amarjeet Kaur as Company Secretary and Compliance Officer Syschem (India) Limited announced the resignation of Amarjeet Kaur, as a Company Secretary and Compliance Officer of the company at its board meeting to be held on November 17, 2020. Announcement • Nov 06
Syschem (India) Limited Announces Board Changes Syschem (India) Limited informed that Mrs. Neena Kumar, has tendered resignation from the position of the Independent Director of the Company with effect from October 30, 2020. Reported Earnings • Nov 01
First half earnings released Over the last 12 months the company has reported total losses of ₹35.1m, with losses widening by ₹34.2m from the prior year. Total revenue was ₹717.1m over the last 12 months, down 20% from the prior year. Announcement • Jul 26
Syschem (India) Limited to Report Q1, 2021 Results on Jul 27, 2020 Syschem (India) Limited announced that they will report Q1, 2021 results on Jul 27, 2020 